• Explore /
  • Poster
  • / Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.

Abstract Poster

Authors

null

Ursula A. Matulonis

Dana-Farber Cancer Institute, Boston, MA

Ursula A. Matulonis , Ana Oaknin , Sandro Pignata , Hannelore denys , Nicoletta Colombo , Toon Van Gorp , Jason A. Konner , Marga Romeo , Philipp Harter , Conleth G. Murphy , Jiuzhou Wang , Michael W. Method , Brooke Esteves , Robert L. Coleman , Domenica Lorusso

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04209855

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5512)

DOI

10.1200/JCO.2022.40.16_suppl.5512

Abstract #

5512

Poster Bd #

391

Abstract Disclosures

Similar Posters

First Author: Lingying Wu

First Author: Isabelle Laure Ray-Coquard

First Author: Leslie M. Randall

First Author: Kathleen N. Moore